Literature DB >> 28087578

Distinct binding of PET ligands PBB3 and AV-1451 to tau fibril strains in neurodegenerative tauopathies.

Maiko Ono1,2, Naruhiko Sahara1, Katsushi Kumata1, Bin Ji1, Ruiqing Ni3, Shunsuke Koga4, Dennis W Dickson4, John Q Trojanowski5, Virginia M-Y Lee5, Mari Yoshida6, Isao Hozumi7, Yasumasa Yoshiyama8, John C van Swieten9, Agneta Nordberg3, Tetsuya Suhara1, Ming-Rong Zhang1, Makoto Higuchi1.   

Abstract

Diverse neurodegenerative disorders are characterized by deposition of tau fibrils composed of conformers (i.e. strains) unique to each illness. The development of tau imaging agents has enabled visualization of tau lesions in tauopathy patients, but the modes of their binding to different tau strains remain elusive. Here we compared binding of tau positron emission tomography ligands, PBB3 and AV-1451, by fluorescence, autoradiography and homogenate binding assays with homologous and heterologous blockades using tauopathy brain samples. Fluorescence microscopy demonstrated intense labelling of non-ghost and ghost tangles with PBB3 and AV-1451, while dystrophic neurites were more clearly detected by PBB3 in brains of Alzheimer's disease and diffuse neurofibrillary tangles with calcification, characterized by accumulation of all six tau isoforms. Correspondingly, partially distinct distributions of autoradiographic labelling of Alzheimer's disease slices with 11C-PBB3 and 18F-AV-1451 were noted. Neuronal and glial tau lesions comprised of 4-repeat isoforms in brains of progressive supranuclear palsy, corticobasal degeneration and familial tauopathy due to N279K tau mutation and 3-repeat isoforms in brains of Pick's disease and familial tauopathy due to G272V tau mutation were sensitively detected by PBB3 fluorescence in contrast to very weak AV-1451 signals. This was in line with moderate 11C-PBB3 versus faint 18F-AV-1451 autoradiographic labelling of these tissues. Radioligand binding to brain homogenates revealed multiple binding components with differential affinities for 11C-PBB3 and 18F-AV-1451, and higher availability of binding sites on progressive supranuclear palsy tau deposits for 11C-PBB3 than 18F-AV-1451. Our data indicate distinct selectivity of PBB3 compared to AV-1451 for diverse tau fibril strains. This highlights the more robust ability of PBB3 to capture wide-range tau pathologies.
© The Author (2017). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Alzheimer’s disease; N279K/G272V FTDP-17-MAPT mutation; PBB3/AV-1451; progressive supranuclear palsy/corticobasal degeneration/Pick’szzm321990 disease; tau PET ligand

Mesh:

Substances:

Year:  2017        PMID: 28087578      PMCID: PMC5837223          DOI: 10.1093/brain/aww339

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  45 in total

1.  Anatomy of disturbed sleep in pallido-ponto-nigral degeneration.

Authors:  Andrew R Spector; Brittany N Dugger; Zbigniew K Wszolek; Ryan J Uitti; Paul Fredrickson; Joseph Kaplan; Bradley F Boeve; Dennis W Dickson; Audrey Strongosky; Siong-Chi Lin
Journal:  Ann Neurol       Date:  2011-06       Impact factor: 10.422

2.  [(18)F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease.

Authors:  Chun-Fang Xia; Janna Arteaga; Gang Chen; Umesh Gangadharmath; Luis F Gomez; Dhanalakshmi Kasi; Chung Lam; Qianwa Liang; Changhui Liu; Vani P Mocharla; Fanrong Mu; Anjana Sinha; Helen Su; A Katrin Szardenings; Joseph C Walsh; Eric Wang; Chul Yu; Wei Zhang; Tieming Zhao; Hartmuth C Kolb
Journal:  Alzheimers Dement       Date:  2013-02-12       Impact factor: 21.566

3.  Clinical-pathologic study of biomarkers in FTDP-17 (PPND family with N279K tau mutation).

Authors:  Zoe Arvanitakis; Robert J Witte; Dennis W Dickson; Yoshio Tsuboi; Ryan J Uitti; Jerzy Slowinski; Michael L Hutton; Siong-Chi Lin; Bradley F Boeve; William P Cheshire; Robert A Pooley; Julie M Liss; John N Caviness; Audrey J Strongosky; Zbigniew K Wszolek
Journal:  Parkinsonism Relat Disord       Date:  2006-12-29       Impact factor: 4.891

4.  Clinical features and disease haplotypes of individuals with the N279K tau gene mutation: a comparison of the pallidopontonigral degeneration kindred and a French family.

Authors:  Yoshio Tsuboi; Ryan J Uitti; Marie-Bernadette Delisle; Joaquim J Ferreira; Christine Brefel-Courbon; Olivier Rascol; Bernardino Ghetti; Jill R Murrell; Michael Hutton; Matthew Baker; Zbigniew K Wszolek
Journal:  Arch Neurol       Date:  2002-06

5.  Tau pathology in two Dutch families with mutations in the microtubule-binding region of tau.

Authors:  M G Spillantini; R A Crowther; W Kamphorst; P Heutink; J C van Swieten
Journal:  Am J Pathol       Date:  1998-11       Impact factor: 4.307

6.  Abnormal Tau proteins in progressive supranuclear palsy. Similarities and differences with the neurofibrillary degeneration of the Alzheimer type.

Authors:  S Flament; A Delacourte; M Verny; J J Hauw; F Javoy-Agid
Journal:  Acta Neuropathol       Date:  1991       Impact factor: 17.088

7.  Characterization of tau positron emission tomography tracer [18F]AV-1451 binding to postmortem tissue in Alzheimer's disease, primary tauopathies, and other dementias.

Authors:  Kerstin Sander; Tammaryn Lashley; Priya Gami; Thibault Gendron; Mark F Lythgoe; Jonathan D Rohrer; Jonathan M Schott; Tamas Revesz; Nick C Fox; Erik Årstad
Journal:  Alzheimers Dement       Date:  2016-02-15       Impact factor: 21.566

Review 8.  Prion-like mechanisms in the pathogenesis of tauopathies and synucleinopathies.

Authors:  Michel Goedert; Ben Falcon; Florence Clavaguera; Markus Tolnay
Journal:  Curr Neurol Neurosci Rep       Date:  2014-11       Impact factor: 5.081

9.  Distinct tau prion strains propagate in cells and mice and define different tauopathies.

Authors:  David W Sanders; Sarah K Kaufman; Sarah L DeVos; Apurwa M Sharma; Hilda Mirbaha; Aimin Li; Scarlett J Barker; Alex C Foley; Julian R Thorpe; Louise C Serpell; Timothy M Miller; Lea T Grinberg; William W Seeley; Marc I Diamond
Journal:  Neuron       Date:  2014-05-22       Impact factor: 17.173

Review 10.  Clinicopathologic assessment and imaging of tauopathies in neurodegenerative dementias.

Authors:  Melissa E Murray; Naomi Kouri; Wen-Lang Lin; Clifford R Jack; Dennis W Dickson; Prashanthi Vemuri
Journal:  Alzheimers Res Ther       Date:  2014-01-02       Impact factor: 6.982

View more
  74 in total

Review 1.  Current Understanding of Neurodegenerative Diseases Associated With the Protein Tau.

Authors:  Keith A Josephs
Journal:  Mayo Clin Proc       Date:  2017-08       Impact factor: 7.616

2.  Ectopic Expression Induces Abnormal Somatodendritic Distribution of Tau in the Mouse Brain.

Authors:  Atsuko Kubo; Shouyou Ueda; Ayaka Yamane; Satoko Wada-Kakuda; Mai Narita; Makoto Matsuyama; Akane Nomori; Akihiko Takashima; Taisuke Kato; Osamu Onodera; Motohito Goto; Mamoru Ito; Takami Tomiyama; Hiroshi Mori; Shigeo Murayama; Yasuo Ihara; Hiroaki Misonou; Tomohiro Miyasaka
Journal:  J Neurosci       Date:  2019-06-24       Impact factor: 6.167

3.  18F-AV-1451 positron emission tomography in neuropathological substrates of corticobasal syndrome.

Authors:  Anna E Goodheart; Joseph J Locascio; Wesley R Samore; Jessica A Collins; Michael Brickhouse; Aaron Schultz; Alexandra Touroutoglou; Keith A Johnson; Matthew P Frosch; John H Growdon; Bradford C Dickerson; Stephen N Gomperts
Journal:  Brain       Date:  2021-02-12       Impact factor: 13.501

Review 4.  Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches.

Authors:  Adam L Boxer; Jin-Tai Yu; Lawrence I Golbe; Irene Litvan; Anthony E Lang; Günter U Höglinger
Journal:  Lancet Neurol       Date:  2017-06-13       Impact factor: 44.182

5.  Imaging of tau deposits in adults with Niemann-Pick type C disease: a case-control study.

Authors:  Victor L Villemagne; D Velakoulis; V Doré; S Bozinoski; C L Masters; C C Rowe; Mark Walterfang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-01-28       Impact factor: 9.236

6.  Fluorescence and autoradiographic evaluation of tau PET ligand PBB3 to α-synuclein pathology.

Authors:  Shunsuke Koga; Maiko Ono; Naruhiko Sahara; Makoto Higuchi; Dennis W Dickson
Journal:  Mov Disord       Date:  2017-04-25       Impact factor: 10.338

7.  Progressive Tau Accumulation in Alzheimer Disease: 2-Year Follow-up Study.

Authors:  Hanna Cho; Jae Yong Choi; Hye Sun Lee; Jae Hoon Lee; Young Hoon Ryu; Myung Sik Lee; Clifford R Jack; Chul Hyoung Lyoo
Journal:  J Nucl Med       Date:  2019-03-29       Impact factor: 10.057

Review 8.  FTD spectrum: Neuroimaging across the FTD spectrum.

Authors:  Jennifer L Whitwell
Journal:  Prog Mol Biol Transl Sci       Date:  2019-06-18       Impact factor: 3.622

Review 9.  The complexity of tau in Alzheimer's disease.

Authors:  Nima N Naseri; Hong Wang; Jennifer Guo; Manu Sharma; Wenjie Luo
Journal:  Neurosci Lett       Date:  2019-04-25       Impact factor: 3.046

Review 10.  Small-molecule PET Tracers for Imaging Proteinopathies.

Authors:  Chester A Mathis; Brian J Lopresti; Milos D Ikonomovic; William E Klunk
Journal:  Semin Nucl Med       Date:  2017-07-13       Impact factor: 4.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.